Phaseline

Companies › Stemline Therapeutics

Stemline Therapeutics: clinical trials, targets and expected readouts

4 active drug programs in 34 registered trials: 16 Phase 2, 14 Phase 1, 4 Phase 3; Oncology; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Elacestrant
Estrogen receptor alpha degrader
ESR1Phase 3Breast Cancer; Metastatic Breast Cancer; Breast Neoplasms; Advanced Breast Cancer …Nov 2026
Tagraxofusp
Interleukin-3 receptor subunit alpha binding agent; Elongation factor 2 inhibitor
IL3RA, EEF2Phase 2Acute Myeloid Leukemia; Blastic Plasmacytoid Dendritic Cell Neoplasm; Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN); Myelofibrosis …Feb 2028
MEN2312
KAT6 inhibitor
KAT6Phase 1Advanced Breast CancerOct 2027
MEN2501–Phase 1Platinum-resistant Ovarian CancerDec 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05596409ElacestrantPhase 2Metastatic Breast CancerOncologyNov 2026
NCT06691035ElacestrantPhase 1Breast Cancer Metastatic Breast CancerOncologyNov 2026
NCT05233618TagraxofuspPhase 1MyelofibrosisOncologyDec 2026
NCT05386108ElacestrantPhase 1Breast NeoplasmsOncologyDec 2026
NCT05982093ElacestrantPhase 2Breast CancerOncologyDec 2026
NCT05563220ElacestrantPhase 1Breast CancerOncologyDec 2026
NCT04216524TagraxofuspPhase 2Blastic Plasmacytoid Dendritic Cell NeoplasmOncologyDec 2026
NCT07159451ElacestrantPhase 2Breast CancerOncologyJan 2027
NCT05038592TagraxofuspPhase 1Chronic Myelomonocytic LeukemiaOncologyJan 2027
NCT06498973TagraxofuspPhase 1Acute Myeloid LeukemiaOncologyApr 2027
NCT03113643TagraxofuspPhase 1Acute Myeloid LeukemiaOncologyMay 2027
NCT07467772ElacestrantPhase 2Uterine SarcomaOncologyJul 2027
NCT06382948ElacestrantPhase 3Advanced Breast CancerOncologySep 2027
NCT06923527ElacestrantPhase 2ER+ Breast CancerOncologySep 2027
NCT06561152TagraxofuspPhase 1Refractory Acute Myeloid LeukemiaOncologyOct 2027
NCT06638307MEN2312Phase 1Advanced Breast CancerOncologyOct 2027
NCT05476770TagraxofuspPhase 1Hematologic MalignancyOncologyNov 2027
NCT07226427MEN2501Phase 1Platinum-resistant Ovarian CancerOncologyDec 2027
NCT06456463TagraxofuspPhase 2Acute Myeloid LeukemiaOncologyFeb 2028
NCT07198724ElacestrantPhase 1Metastatic Breast CancerOncologyJun 2028
NCT06062498ElacestrantPhase 2Estrogen-receptor-positive Breast CancerOncologyJul 2028
NCT07209449ElacestrantPhase 2Endometrial CancerOncologyOct 2028
NCT07766018ElacestrantPhase 2Breast CancerOncologyOct 2028
NCT06075953ElacestrantPhase 2Ductal Carcinoma in SituOncologyNov 2028
NCT07007052TagraxofuspPhase 2Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)OncologyDec 2028
NCT07395336ElacestrantPhase 2Breast CancerOncologyDec 2028
NCT06201234ElacestrantPhase 2Hormone Receptor Positive HER-2 Negative Breast CancerOncologyDec 2028
NCT07148180TagraxofuspPhase 1Acute Myeloid Leukaemia (AML)OncologyDec 2028
NCT07612215ElacestrantPhase 1ER Positive, HER2 Positive Breast CancerOncologyMay 2029
NCT06492616ElacestrantPhase 3Breast CancerOncologyAug 2029
NCT07222215ElacestrantPhase 2Estrogen-receptor-positive Breast CancerOncologyDec 2029
NCT05442216TagraxofuspPhase 2Acute Myeloid LeukemiaOncologyJul 2030
NCT05512364ElacestrantPhase 3ER-positive Breast CancerOncologyNov 2032
NCT07242352ElacestrantPhase 3Breast CancerOncologySep 2033

Targets

ESR1 (1) IL3RA (1) EEF2 (1) KAT6 (1)

Companies with the same targets

Pfizer AstraZeneca Roche Eurofarma Laboratorios Eli Lilly Shanghai Best-Link Bioscience Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair Atossa Therapeutics GE Healthcare Novartis

Companies built like this

Olema Pharmaceuticals CStone Pharmaceuticals Shenzhen TargetRx Lantheus Medical Imaging Day One Biopharmaceuticals

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.